Literature DB >> 22397659

Discontinuing donepezil or starting memantine for Alzheimer's disease.

Lon S Schneider.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22397659     DOI: 10.1056/NEJMe1200429

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.

Authors:  Joshua D Vardigan; Christopher E Cannon; Vanita Puri; Mandy Dancho; AmyJo Koser; Marion Wittmann; Scott D Kuduk; John J Renger; Jason M Uslaner
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

2.  Patterns and determinants of dementia pharmacotherapy in a population-based cohort of home care clients.

Authors:  Colleen J Maxwell; Mary Vu; David B Hogan; Scott B Patten; Micaela Jantzi; Marie-Jeanne Kergoat; Nathalie Jetté; Susan E Bronskill; George Heckman; John P Hirdes
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

Review 3.  Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.

Authors:  Muriel Noetzli; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

4.  Inappropriate drugs in elderly patients with severe cognitive impairment: results from the shelter study.

Authors:  Giuseppe Colloca; Matteo Tosato; Davide L Vetrano; Eva Topinkova; Daniela Fialova; Jacob Gindin; Henriëtte G van der Roest; Francesco Landi; Rosa Liperoti; Roberto Bernabei; Graziano Onder
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.